Beacon Therapeutics reported that its gene therapy laruparetigene zovaparvovec met the FDA-endorsed primary endpoint in its pivotal Phase II/III VISTA study in X-linked retinitis pigmentosa. The company said responder rates on low-luminance visual acuity (LLVA) favored the higher- and lower-dose cohorts, supporting its push toward a biologics license application. The results intensify focus on the durability and functional vision outcomes needed for regulatory consideration in rare ocular genetics. Beacon’s reporting also adds to investor and clinician attention on how gene therapies translate into clinically meaningful endpoints like LLVA gains over time. In parallel, Beacon is preparing additional regulatory steps following the pivotal trial readout, positioning laruparetigene zovaparvovec as a near-term potential approval candidate in XLRP after years of competitive setbacks across the category.